Non-small cell lung cancer: Whole-body MR examination for M-stage assessment - Utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT

Radiology

Volumn 248, Issue 2, 2008, Pages 643-654

  Ohno, Yoshiharu ^a   Koyama, Hisanobu ^a   Onishi, Yumiko ^b   Takenaka, Daisuke ^a   Nogami, Munenobu ^b   Yoshikawa, Takeshi ^a,c   Matsumoto, Sumiaki ^a   Kotani, Yoshikazu ^a   Sugimura, Kazuro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c Konan Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; GADOTERIDOL; CONTRAST MEDIUM; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; HETEROCYCLIC COMPOUND; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; IMAGING SYSTEM; INTERMETHOD COMPARISON; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGIST; WHOLE BODY IMAGING; ANALYSIS OF VARIANCE; CANCER STAGING; COMPARATIVE STUDY; IMAGE PROCESSING; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; ROC CURVE; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CARCINOMA, NON-SMALL-CELL LUNG; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HETEROCYCLIC COMPOUNDS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 49049115378     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2482072039     Document Type: Article

References (43)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Melamed MR, Flehinger BJ, Zaman MB. Impact of early detection on the clinical course of lung cancer. Surg Clin North Am 1987;67:909-924.
3. Deslauriers J. Current surgical treatment of nonsmall cell lung cancer 2001. Eur Respir J Suppl 2002;35:61s-70s.
4. Krupnick AS, Kreisel D, Hope A, Bradley J, Govindan R, Meyers B. Recent advances and future perspectives in the management of lung cancer. Curr Probl Surg 2005;42:540-610.
5. Hustinx R, Benard F, Alavi A. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 2002;32:35-46.
6. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-2507.
7. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004;78:1017-1023.
8. Halpern BS, Schiepers C, Weber WA, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 2005;128:2289-2297.
9. Walker R, Kessar P, Blanchard R, et al. Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging 2000;11:343-350.
10. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177:229-236.
11. Barkhausen J, Quick HH, Lauenstein T, et al. Whole-body MR imaging in 30 seconds with real-time true FISP and a continuously rolling table platform: feasibility study. Radiology 2001;220:252-256.
12. Mazumdar A, Siegel MJ, Narra V, Luchtman-Jones L. Whole-body fast inversion recovery MR imaging of small cell neoplasms in pediatric patients: a pilot study. AJR Am J Roentgenol 2002;179:1261-1266.
13. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology 2004;233:139-148.
14. Ohno Y, Koyama H, Nogami M, et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging 2007;26:498-509.
15. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F; and the American College of Chest Physicians. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003;123(1 suppl):147S-156S.
16. Korobkin M, Lombardi TJ, Aisen AM, et al. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology 1995;197:411-418.
17. Yokoi K, Kamiya N, Matsuguma H, et al. Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest 1999;115:714-719.
18. Earnest F 4th, Ryu JH, Miller GM, et al. Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection - pilot study. Radiology 1999;211:137-145.
19. Remer EM, Obuchowski N, Ellis JD, Rice TW, Adelstein DJ, Baker ME. Adrenal mass evaluation in patients with lung carcinoma: a cost-effectiveness analysis. AJR Am J Roentgenol 2000;174:1033-1039.
20. Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003;226:181-187.
21. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007;25:146-152.
22. Matoba M, Tonami H, Kondou T, et al. Lung carcinoma: diffusion-weighted MR imaging - preliminary evaluation with apparent diffusion coefficient. Radiology 2007;243:570-577.
23. Abdel Razek AA, Soliman NY, Elkhamary S, Alsharaway MK, Tawfik A. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006;16:1468-1477.
24. Nasu K, Kuroki Y, Nawano S, et al. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006;239:122-130.
25. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 2004;22:275-282.
26. Charles-Edwards EM, deSouza NM. Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging 2006;6:135-143.
27. Schellinger PD, Fiebach JB, Hacke W. Imaging-based decision making in thrombolytic therapy for ischemic stroke: present status. Stroke 2003;34:575-583.
28. Brunel H, Girard N, Confort-Gouny S, et al. Fetal brain injury. J Neuroradiol 2004;31:123-137.
29. Rosenbloom M, Sullivan EV, Pfefferbaum A. Using magnetic resonance imaging and diffusion tensor imaging to assess brain damage in alcoholics. Alcohol Res Health 2003;27:146-152.
30. Lee SK, Kim DI, Kim J, et al. Diffusion-tensor MR imaging and fiber tractography: a new method of describing aberrant fiber connections in developmental CNS anomalies. RadioGraphics 2005;25:53-65.
31. Svanholm H, Starklint H, Gundersen HJ, Fabricius J, Barlebo H, Olsen S. Reproducibility of histomorphologic diagnoses with special reference to the kappa statistic. APMIS 1989;97:689-698.
32. Aquino SL, Kuester LB, Muse VV, Halpern EF, Fischman AJ. Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT. Eur J Nucl Med Mol Imaging 2006;33:692-696.
33. Meirelles GS, Erdi YE, Nehmeh SA, et al. Deep-inspiration breath-hold PET/CT: clinical findings with a new technique for detection and characterization of thoracic lesions. J Nucl Med 2007;48:712-719.
34. Griffeth LK, Rich KM, Dehdashti F, et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 1993;186:37-44.
35. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-332.
36. Komori T, Narabayashi I, Matsumura K, et al. 2-[Fluorine-18]-fluoro-2- deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med 2007;21:209-215.
37. Lichy MP, Aschoff P, Plathow C, et al. Tumor detection by diffusion-weighted MRI and ADC-mapping: initial clinical experiences in comparison to PET-CT. Invest Radiol 2007;42:605-613.
38. DeVita VT Jr, Young RC, Canellos GP. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 1975;35:98-110.
39. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1004.
40. Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995;6:3-18.
41. Gerth HU, Juergens KU, Dirksen U, Gerss J, Schober O, Franzius C. Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. J Nucl Med 2007;48:1932-1939.
42. Tateishi U, Yamaguchi U, Seki K, Terauchi T, Arai Y, Kim EE. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Radiology 2007;245:839-847.
43. Fonti R, Salvatore B, Quarantelli M, et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 2008;49:195-200.